Clinical trials: Intranasal Administration
Epistaxis
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
Between 10 and 12% of the general population suffers from epistaxis, out of which 10% would need to be medically managed. Most of patients treated for epistaxis are managed through emergency departments.
- Trial name
- BATSI (NCT03912051)
- Testing
- asymmetric balloon
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Dianosic
Migraine, Migraine Headache
Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine
The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a…
- Conditions
- Migraine, Migraine Headache, Migraine Disorders, Migraine With Aura
- Trial name
- NCT00285402
- Testing
- AST-726 Low dose, AST-726 High dose
- Where
- 19 sites in Finland, Netherlands and 1 more
- Volunteers
- 198 people
- Sponsor
- Ariston Pharmaceuticals, Inc.
Preterm Delivery, Inadequate Milk Production
Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
Induction and support of lactation in women with preterm delivery and inadequate milk production.
- Trial name
- MERMAID (NCT02545127)
- Testing
- Merotocin
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Ferring Pharmaceuticals
Influenza A
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
The primary objective is to determine the dose level of live, wild-type A/California/ H1N1 2009 virus that has an appropriate safety and illness/infectivity profile to be used as an influenza virus, challenge strain in future…
- Trial name
- NCT02014870
- Testing
- 1:1000 Live wild-type A/California/H1N1 2009, 1:100 Live wild-type A/California/H1N1 2009, 1:10 Live wild-type A/California/H1N1 2009
- Where
- Belgium
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
High Frequency Episodic Migraine and Chronic Migraine
TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine
This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.
- Trial name
- NCT01839149
- Testing
- TI-001
- Where
- 6 sites in Australia, Chile and 1 more
- Volunteers
- 240 people
- Sponsor
- Trigemina, Inc
Migraine
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
The purpose of this study to show that zavegepant 10 milligrams given through the nose provides: freedom from pain, 2 hours after taking the medicine for the first migraine attack.
- Trial name
- NCT06103734
- Testing
- Zavegepant 10 mg
- Sponsor
- Pfizer
Male Hypogonadism
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
The purpose of this study is to determine the efficacy (based on the pharmacokinetic profile of testosterone) and safety of TBS-1 in the treatment of hypogonadal men
- Trial name
- NCT01446042
- Testing
- Testosterone
- Where
- 30 sites in United States
- Volunteers
- 306 people
- Sponsor
- Acerus Pharmaceuticals Corporation
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Healthy Male Adults
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Oxytocin (OT) is a small, naturally occurring peptide currently in clinical use to stimulate lactation in breastfeeding women. The intranasal administration of OT has recently attracted attention as a potential novel treatment in…
- Trial name
- NCT01983514
- Testing
- 8IU intranasal oxytocin, 24 IU intranasal oxytocin, 1 IU intravenous oxytocin
- Where
- Norway
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- OptiNose AS
Rhinitis, Allergic, Seasonal
Study In Adults And Adolescents With Seasonal Allergic Rhinitis.
Compare the efficacy and safety of an investigational nasal spray compared with placebo nasal spray in the treatment of seasonal allergic rhinitis.
- Trial name
- NCT00225823
- Testing
- GW685698X
- Where
- 24 sites in Estonia, Latvia and 4 more
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Depression
A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression
The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD)…
- Trial name
- NCT02918318
- Testing
- Intranasal esketamine (28 mg), Intranasal esketamine (56 mg), Intranasal esketamine (84 mg)
- Where
- 43 sites in Japan
- Volunteers
- 202 people
- Sponsor
- Janssen Pharmaceutical K.K.
Migraine
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
The purpose of this study is: To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet…
- Trial name
- NCT01507610
- Testing
- Sumatriptan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Optinose US Inc.
COVID-19
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
This is prospective double-blind study in the United States is designed to investigate the efficacy and safety of a single dose of COVI-DROPS or matched placebo in outpatient adults with mild symptoms associated with COVID-19 and…
- Trial name
- US (NCT05074394)
- Testing
- COVI-DROPS
- Sponsor
- Sorrento Therapeutics, Inc.
Dry Eye Syndromes
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye…
- Trial name
- NCT02313454
- Testing
- Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Allergan
Focus: Bioavailability
Characterization of Cyanocobalamin in Healthy Voluteers After Intranasal and Intramuscual Administration
The main purpose of this study is to assess the relative bioavailability of Nascobal Nasal Spray as compared to an IM injection of cyanocobalamin (European reference product).
- Trial name
- NCT01306123
- Testing
- Nascobal nasal spray (cyanocobalamin, USP), Vitamin B12-ratiopharm N, injection solution
- Where
- Sweden
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Swedish Orphan Biovitrum
Covid19
A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers
This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via the…
- Trial name
- NCT04839042
- Testing
- SC-Ad6-1
- Where
- Australia
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Moat Biotechnology Corporation
Osteoporosis, Osteopenia
Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone Mass
This study is being conducted to evaluate the effect treatment has on serum P1NP levels, a biomarker of bone formation in postmenopausal women with low bone mass.
- Trial name
- NCT01604057
- Testing
- ZT-034 Low Dose Nasal Spray, ZT-034 Mid Dose Nasal Spray, ZT-034 High Dose Nasal Spray
- Volunteers
- 130 people
- Sponsor
- Azelon Pharmaceuticals
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Covid19
Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
The purpose of this study is to assess the safety and efficacy of UNI91103 intranasal spray for treatment of coronavirus disease 2019 (COVID-19) in asymptomatic or mildly symptomatic adults.
- Trial name
- PREVENT (NCT04932915)
- Testing
- Niclosamide
- Where
- 3 sites in Germany
- Volunteers
- 4 people
- Sponsor
- UNION therapeutics
Mild to Moderate Asthma
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
To compare the systemic exposure of a single dose of 400 µg of OPTINOSE FLUTICASONE with 440 µg of Flovent® HFA (fluticasone propionate) Inhalation Aerosol in asthmatic subjects.
- Trial name
- NCT02266927
- Testing
- Flovent HFA, OPTINOSE™ FLUTICASONE
- Where
- Ireland
- Volunteers
- 28 people
- Sponsor
- Optinose US Inc.